SCHEMBL977926

SCHEMBL977926

O=C(O)CC1(c2ccccc2)CCCC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.69
DPP4 P27487 1/20 0.57
LMNA P02545 6/20 0.56
TSHR P16473 1/20 0.55
L3MBTL1 Q9Y468 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
AKR1C1 Q04828 1/20 0.52
SLC6A4 P31645 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HSD17B10 Q99714 1/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A3 Q01959 1/20 0.50
EPHX2 P34913 1/20 0.50
ALDH1A1 P00352 1/20 0.49
POLB P06746 1/20 0.49
MAPK1 P28482 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365797 0.98 HSD11B1 (0.72) HSD11B1DPP4LMNATSHRL3MBTL1
Hydrochloric Acid SCHEMBL11526870 0.96 HSD11B1 (0.70) HSD11B1DPP4LMNATSHRL3MBTL1
SCHEMBL625584 0.96 HSD11B1 (0.64) HSD11B1DPP4LMNATSHRL3MBTL1
SCHEMBL1361875 0.92 TSHR (0.58) HSD11B1DPP4LMNATSHRL3MBTL1
Di(Hydroxyethyl)Ether SCHEMBL28932504 0.87 HSD11B1 (0.55) HSD11B1DPP4LMNATSHRL3MBTL1
SCHEMBL27690381 0.85 LMNA (0.54) HSD11B1DPP4LMNAL3MBTL1SMN1; SMN2
SCHEMBL6585284 0.85 DPP4 (0.53) HSD11B1DPP4LMNAL3MBTL1SMN1; SMN2
SCHEMBL2644998 0.85 DPP4 (0.53) HSD11B1DPP4LMNAL3MBTL1SMN1; SMN2
SCHEMBL4866308 0.85 DPP4 (0.58) HSD11B1DPP4LMNAL3MBTL1SMN1; SMN2
SCHEMBL11611383 0.83 SLC6A4 (0.54) HSD11B1DPP4LMNATSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 US claimed
US-9217012-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-12-22 US claimed
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) 2012-04-12 US claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 WO claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 US claimed
WO-2009141384-A2 PROCESS FOR THE PURIFICATION OF FACTOR VII POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS NOVO NORDISK A/S (DK) 2009-11-26 WO claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
US-12551555-B2 Compositions and methods for potentiating immune activity KUMQUAT BIOSCIENCES INC. (US) 2026-02-17 US disclosed
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP disclosed
EP-0632036-A2 Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses SANKYO COMPANY LIMITED (JP) 1995-01-04 EP disclosed
US-4172093-A Pharmacodynamically active indan derivatives AB KABI (SE) 1979-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS HSD11B1 3994/4885DPP4 853/4885LMNA 4734/4885
US-12551555-B2 Compositions and methods for potentiating immune activity PTPRCAP, PTPN2, PTPRC HSD11B1 4517/4885DPP4 1843/4885LMNA 4799/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS HSD11B1 3994/4885DPP4 853/4885LMNA 4734/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 HSD11B1 1871/4885DPP4 2211/4885LMNA 1769/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 HSD11B1 3809/4885DPP4 1780/4885LMNA 2024/4885
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS HSD11B1 3994/4885DPP4 853/4885LMNA 4734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.